120 related articles for article (PubMed ID: 9718230)
1. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
Schmidt BH; Heinig R
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230
[TBL] [Abstract][Full Text] [Related]
2. Metrifonate: a new agent for the treatment of Alzheimer's disease.
Williams BR
Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
[TBL] [Abstract][Full Text] [Related]
4. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
Heinig R; Sachse R
Int J Clin Pharmacol Ther; 1999 Sep; 37(9):456-64. PubMed ID: 10507245
[TBL] [Abstract][Full Text] [Related]
5. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacology of metrifonate.
Jann MW
Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
[TBL] [Abstract][Full Text] [Related]
8. Evaluating response to metrifonate.
Tariot PN
J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
[TBL] [Abstract][Full Text] [Related]
9. Metrifonate for Alzheimer's disease patients.
Schneider LS
J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
[No Abstract] [Full Text] [Related]
10. Metrifonate: overview of safety and efficacy.
Cummings JL
Pharmacotherapy; 1998; 18(2 Pt 2):43-6; discussion 79-82. PubMed ID: 9543464
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
12. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
13. Metrifonate: update on a new antidementia agent.
Ringman JM; Cummings JL
J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
[TBL] [Abstract][Full Text] [Related]
14. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Gélinas I; Gauthier S; Cyrus PA
J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
[TBL] [Abstract][Full Text] [Related]
15. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
Piecoro LT; Wermeling DP; Schmitt FA; Ashford JW
Pharmacotherapy; 1998; 18(5):1129-32. PubMed ID: 9758325
[TBL] [Abstract][Full Text] [Related]
16. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
[TBL] [Abstract][Full Text] [Related]
17. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Sandson TA
Neurology; 1999 Feb; 52(3):675-6. PubMed ID: 10025821
[No Abstract] [Full Text] [Related]
18. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
19. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Knopman DS
Neurology; 1998 May; 50(5):1203-5. PubMed ID: 9595961
[No Abstract] [Full Text] [Related]
20. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
Blass JP; Cyrus PA; Bieber F; Gulanski B
Alzheimer Dis Assoc Disord; 2000; 14(1):39-45. PubMed ID: 10718203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
